235 related articles for article (PubMed ID: 27322617)
1. Purinergic Signaling as a Regulator of Th17 Cell Plasticity.
Fernández D; Flores-Santibáñez F; Neira J; Osorio-Barrios F; Tejón G; Nuñez S; Hidalgo Y; Fuenzalida MJ; Meza D; Ureta G; Lladser A; Pacheco R; Acuña-Castillo C; Guixé V; Quintana FJ; Bono MR; Rosemblatt M; Sauma D
PLoS One; 2016; 11(6):e0157889. PubMed ID: 27322617
[TBL] [Abstract][Full Text] [Related]
2. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.
Wang LL; Tang HP; Shi GC; Wan HY; Tang W; Hou XX; Pan LN; Shi BY; Tao LQ
Mol Med Rep; 2013 Nov; 8(5):1432-8. PubMed ID: 24065069
[TBL] [Abstract][Full Text] [Related]
3. CD39+ regulatory T cells attenuate allergic airway inflammation.
Li P; Gao Y; Cao J; Wang W; Chen Y; Zhang G; Robson SC; Wu Y; Yang J
Clin Exp Allergy; 2015 Jun; 45(6):1126-37. PubMed ID: 25728362
[TBL] [Abstract][Full Text] [Related]
4. CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease.
Liberal R; Grant CR; Ma Y; Csizmadia E; Jiang ZG; Heneghan MA; Yee EU; Mieli-Vergani G; Vergani D; Robson SC; Longhi MS
J Autoimmun; 2016 Aug; 72():102-12. PubMed ID: 27210814
[TBL] [Abstract][Full Text] [Related]
5. Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α-dependent pathways.
Morianos I; Trochoutsou AI; Papadopoulou G; Semitekolou M; Banos A; Konstantopoulos D; Manousopoulou A; Kapasa M; Wei P; Lomenick B; Belaidi E; Kalamatas T; Karageorgiou K; Doskas T; Sallusto F; Pan F; Garbis SD; Quintana FJ; Xanthou G
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12269-12280. PubMed ID: 32409602
[TBL] [Abstract][Full Text] [Related]
6. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
[TBL] [Abstract][Full Text] [Related]
7. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis.
Grant CR; Liberal R; Holder BS; Cardone J; Ma Y; Robson SC; Mieli-Vergani G; Vergani D; Longhi MS
Hepatology; 2014 Mar; 59(3):1007-15. PubMed ID: 23787765
[TBL] [Abstract][Full Text] [Related]
8. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function.
Lee JJ; Jeong HJ; Kim MK; Wee WR; Lee WW; Kim SU; Sung C; Yang YH
Purinergic Signal; 2014; 10(2):357-65. PubMed ID: 24043462
[TBL] [Abstract][Full Text] [Related]
9. CD39/CD73/A2a Adenosine Metabolic Pathway: Targets for Moxibustion in Treating DSS-Induced Ulcerative Colitis.
Zhu Y; Zhuang Z; Wu Q; Lin S; Zhao N; Zhang Q; Xie L; Yu S
Am J Chin Med; 2021; 49(3):661-676. PubMed ID: 33683190
[TBL] [Abstract][Full Text] [Related]
10. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099
[TBL] [Abstract][Full Text] [Related]
11. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
[TBL] [Abstract][Full Text] [Related]
12. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.
Chalmin F; Mignot G; Bruchard M; Chevriaux A; Végran F; Hichami A; Ladoire S; Derangère V; Vincent J; Masson D; Robson SC; Eberl G; Pallandre JR; Borg C; Ryffel B; Apetoh L; Rébé C; Ghiringhelli F
Immunity; 2012 Mar; 36(3):362-73. PubMed ID: 22406269
[TBL] [Abstract][Full Text] [Related]
13. CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism.
Ye ZJ; Zhou Q; Zhang JC; Li X; Wu C; Qin SM; Xin JB; Shi HZ
Respir Res; 2011 Jun; 12(1):77. PubMed ID: 21663645
[TBL] [Abstract][Full Text] [Related]
14. Purinergic signaling during intestinal inflammation.
Longhi MS; Moss A; Jiang ZG; Robson SC
J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
[TBL] [Abstract][Full Text] [Related]
15. CD39 and CD161 modulate Th17 responses in Crohn's disease.
Bai A; Moss A; Kokkotou E; Usheva A; Sun X; Cheifetz A; Zheng Y; Longhi MS; Gao W; Wu Y; Robson SC
J Immunol; 2014 Oct; 193(7):3366-77. PubMed ID: 25172498
[TBL] [Abstract][Full Text] [Related]
16. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.
Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC
Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325
[TBL] [Abstract][Full Text] [Related]
17. Beyond ecto-nucleotidase: CD39 defines human Th17 cells with CD161.
Bai A; Robson S
Purinergic Signal; 2015 Sep; 11(3):317-9. PubMed ID: 26059452
[TBL] [Abstract][Full Text] [Related]
18. Circulating mycobacterial-reactive CD4+ T cells with an immunosuppressive phenotype are higher in active tuberculosis than latent tuberculosis infection.
Kim K; Perera R; Tan DB; Fernandez S; Seddiki N; Waring J; French MA
Tuberculosis (Edinb); 2014 Sep; 94(5):494-501. PubMed ID: 25095750
[TBL] [Abstract][Full Text] [Related]
19. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.
Mandapathil M; Szczepanski MJ; Szajnik M; Ren J; Lenzner DE; Jackson EK; Gorelik E; Lang S; Johnson JT; Whiteside TL
Clin Cancer Res; 2009 Oct; 15(20):6348-57. PubMed ID: 19825957
[TBL] [Abstract][Full Text] [Related]
20. A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production.
Kaku H; Cheng KF; Al-Abed Y; Rothstein TL
J Immunol; 2014 Dec; 193(12):5904-13. PubMed ID: 25392527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
